Surgery

Poor initial visual acuity and clock hours of retinitis were significantly associated with RD development, according to new findings.

Men and patients aged 65 years and younger had higher incidences of retinal tears.

The Massachusetts General Hospital investigator discusses how LVADs and mechanical circulatory supports have altered the national heart donor strategy.

71.6% of patients showed a clinically meaningful improvement in total corneal fluorescein staining at 4 weeks after using the ophthalmic solution.

Dexamethasone as a first-line treatment for DME may increase economic costs in settings where bevacizumab is used off-label, but lower annual costs compared with aflibercept.

Rural patients identifying as Black had a more than 10% absolute increased risk of major leg amputation or death compared with the overall cohort with diabetic foot ulcers.

Hemoglobin changes and the degree of surgery difficulty were significantly lower in the lidocaine plus epinephrine group compared with placebo.

The long-term efficacy of fundoplication surgery has not previously been explored for the management of the symptoms of GERD.

Data show 80% of included patients had an increase of more than 20 points in Kansas City Cardiomyopathy Questionnaire summary scores.

Interventions could be utilized in patients awaiting liver transplantations to avoid further complications or mortality.

After 15 years and 18 patents, the new biotechnology developed by Ariste Medical receives FDA approval to assist in healing ventral hernia repair, one of the most common surgeries.

Mean follow-up IOP was similar between groups, with a median of 15.83 mm Hg among patients with glaucoma versus 14.94 mm Hg among healthy participants.

April 6 is Donate Life Living Donor Day, a day to promote liver donations.

In a new interview from ACC 2022, Florian Rader, MD discusses the potential of the new medication for HCM and the need to monitor safety signals over the long-term.

Findings from VALOR-HCM suggest more data is needed to assess the durability of improvement in septal reduction therapy eligibility over longer time periods.

The costs related to Medicare for OACC increased by about 4% between 2012-2017 for patients with end-stage kidney disease for kidney transplantation.

Dr. Bailey highlights the innovative nature of the procedure and breaks down the process at his institution.

The resolution of excess central retinal thickness in response to anti-VEGF therapy and the treatment burden were additionally similar between the 2 groups.

The lens is added to a patient’s eye through a quick surgical procedure with no removal of corneal tissue and can be removed by a doctor if desired.

Dr. Lee highlights the process of identifying CTEPH and the patient population, as well as the available treatments for the condition.

Trauma patients and patients treated with combination ABX therapy were at an increased risk of C difficile infections.

Levels of troponin after cardiac surgery associated with increased risk of death were higher than levels recommended to define periprocedural myocardial injury.

The heart transplant from a genetically modified pig was initially considered a success and represented new hope for Americans requiring transplants.

Data show the 5-year cumulative incidence of glaucoma was 46% among children with bilateral aphakia and 25% with unilateral aphakia.

Data show ≥60% of eligible faricimab patients with DME could extend treatment to every 4 months, while 95% of ranibizumab implants in wetAMD treatment maintained a six-month schedule.

New guidelines recommend healthcare providers develop and implement an individualized nutrition care plan for individuals with diabetes with or at risk of a DFU.

Dr. Brown discusses the most common conditions of patients treated for ocular trauma and highlights the range of performed procedures in the ED.

Dr. Modi discusses the pending approval of faricimab for nAMD, DME treatment and highlights important observations from phase 3 data.

Outlook Therapeutics is expected to submit a BLA to the FDA for the investigative ophthalmic bevacizumab-vikg formulation (ONS-5010).

TENAYA and LUCERNE show reduced treatment burden in nAMD patients, while vision gains and extended durability for DME patients were observed in YOSEMITE and RHINE.